NOBRXIOL
Dead / Abandoned — Abandoned — no statement of use filed (as of 17 Oct 2025)
What this means for you
This application is over — abandoned 17 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98164969
- Mark type
- Stylized text
- Filed
- 05 Sept 2023
- Published for opposition
- 04 Jun 2024
- Abandoned
- 17 Oct 2025
- Attorney of record
- Patrick J Halloran
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical substances for the treatment of epilepsy, convulsions, seizures, Dravet syndrome, Lennox-Gastaut syndrome, intractable childhood epilepsy with generalized tonic-clonic seizures, generalized epilepsy with febrile seizures plus pharmaceutical preparations and substances for the treatment of pediatric epilepsy
Owner
- Virpax Pharmaceuticals Inc., Berwyn, PA, US
- Virpax Pharmaceuticals Inc., Berwyn, PA, US
Prosecution history
- 17 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 17 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 27 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Dec 2024 — SOU EXTENSION 1 GRANTED
- 27 Dec 2024 — SOU EXTENSION 1 FILED
- 27 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 30 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Jun 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Jun 2024 — PUBLISHED FOR OPPOSITION
- 15 May 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 May 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 May 2024 — ASSIGNED TO EXAMINER
- 28 Sept 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 08 Sept 2023 — NEW APPLICATION ENTERED